Denali Therapeutics shared that it made $17.8 million from ABLEA sales last quarter, beating expectations.

Nov 3, 2026, 7:21 PM ETResultsRead the original at Benzinga

Good for DNLI

Denali’s ABLEA sales beat expectations, and management expects higher sales in Q4. Several clinical readouts are not due until 2027, but new product sales and cash support the company’s plans.

DNLI · Denali Therapeutics

AI read · Good for DNLI

The AI's read

ABLEA gives Denali a new source of sales and shows its brain-delivery approach can support an approved medicine. More growth depends on clinical programs, and several data reports are expected in 2027. The company says its cash can fund plans through 2028.

Get alerts for DNLI

Follow Denali Therapeutics (DNLI) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for DNLI

Free on the App Store and Google Play, or on the web.